Global Antibody and Recombinant Protein CDMO Market Growth (Status and Outlook) 2023-2029

Researcher's newest research report, the “Antibody and Recombinant Protein CDMO Industry Forecast” looks at past sales and reviews total world Antibody and Recombinant Protein CDMO sales in 2022, providing a comprehensive analysis by region and market sector of projected Antibody and Recombinant Protein CDMO sales for 2023 through 2029. With Antibody and Recombinant Protein CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody and Recombinant Protein CDMO industry.

This Insight Report provides a comprehensive analysis of the global Antibody and Recombinant Protein CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Antibody and Recombinant Protein CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody and Recombinant Protein CDMO market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody and Recombinant Protein CDMO and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody and Recombinant Protein CDMO.

The global Antibody and Recombinant Protein CDMO market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Antibody and Recombinant Protein CDMO is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Antibody and Recombinant Protein CDMO players cover Batavia Biosciences, Grifols, Cerbios-Pharma SA, HALIX, Biovian Oy, Catalent, Goodwin Biotechnology, Merck and Hangzhou Hs-biopharm, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Antibody and Recombinant Protein CDMO market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Antibody CDMO

Recombinant Protein CDMO

Segmentation by application

Pharmaceutical Company

Biotechnology Company

Generic Company

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Batavia Biosciences

Grifols

Cerbios-Pharma SA

HALIX

Biovian Oy

Catalent

Goodwin Biotechnology

Merck

Hangzhou Hs-biopharm

Wuxibiologics

Bioinnobio

Thousand Oaks Biopharmaceuticals

Cerbios-Pharma SA

Eurogentec

HJB

Bibo Pharma

MabPlex International

Genscriptprobio

Vetter

Etinpro (Beijing) Co

Boehringer Ingelheim BioXcellence

Lonza

3SBio Inc

Porton